2018 Association for Molecular Pathology (AMP)
Visit HTG at booth 1008 at the 2018 Annual AMP meeting to learn how our collaborators are innovating next-generation pathology with the NGS-based HTG EdgeSeq system and assays.
News & Events
2018 European Congress of Pathology (ECP)
Join HTG for our symposium at ECP on Monday, September 18, 2018 to learn about Next-generation tumor molecular profiling, practical cases.
2018 American Society of Clinical Oncology (ASCO)
HTG’s 1:1 Promise Cdx Partnerships, Personalized.
HTG will be at the 2018 ASCO Annual Meeting. Stop by and learn how our NGS-based HTG EdgeSeq chemistry and automation can help shape the future of oncology.
McCormick Place | Chicago, IL | June 1 - June 5 | Booth #4113 | Meeting Room MR1 on Exhibit Hall Floor
2018 Société Francophone De Chirurgie Oncologiqe (SFCO)
Join HTG at the 2018 SFCO Conference and learn more about our NGS-based sequencing assays that are automated on the HTG EdgeSeq system.
Palais Des Congres | Atlantia, FR | March 29 - March 31, 2018
HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN GeneReader NGS System
TUCSON, Ariz., March 23, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology has been successfully adapted for use with the QIAGEN GeneReader NGS System based on the results of initial technical feasibility tests. Results from samples tested with the HTG EdgeSeq DLBCL Cell of Origin Assay gene panel adapted for detection with the GeneReader NGS System showed strong correlation (r = 0.98) to data previously generated on the MiSeq sequencer.
HTG Molecular Diagnostics and Firalis Announce Agreement to Develop a Theranostic Tool to Predict Response to Anti-TNF-alpha Therapies for Rheumatoid Arthritis
TUCSON, Ariz. and HUNINGUE, France, July 06, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products to biopharma, to biotechnology companies, and to academia, today announced an agreement to develop a next‑generation sequencing (NGS)-based theranostic tool to identify likely non-responders from responders to anti‑TNFα therapy for rheumatoid arthritis (RA).
HTG Molecular Diagnostics Announces Distribution Agreements with Gamidor in Israel and Durviz in Spain and Portugal
TUCSON, Ariz., April 11, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products.
Page last updated March 20, 2023